Source comparison
Tesamorelin for Telehealth Clinicians: Peptide Type Comparison
Tesamorelin GHRH agonist. Stimulates pulsatile GH release HIV lipodystrophy (FDA-approved); off-label metabolic health 15–18% VAT reduction at 26 weeks (EGRIFTA trials) 2mg SQ daily, evening; requires reconstitution $300–$600 (compounded); $1,200–$2,400 (brand
This comparison does not assign a generated winner or score.
- Tesamorelin
- GHRH agonist. Stimulates pulsatile GH release
- HIV lipodystrophy (FDA-approved); off-label metabolic health
- 15–18% VAT reduction at 26 weeks (EGRIFTA trials)
- 2mg SQ daily, evening; requires reconstitution
- $300–$600 (compounded); $1,200–$2,400 (branded)
- Best evidence for VAT-specific reduction; higher cost and reconstitution complexity limit accessibility
- CJC-1295 (DAC)
- GHRH agonist with extended half-life (drug affinity complex)
- Off-label GH optimisation
- Limited clinical trial data; anecdotal VAT reduction
- 1–2mg SQ weekly
- $150–$300
- Longer dosing interval improves compliance but lacks FDA approval and published VAT reduction data
- Ipamorelin
- Ghrelin mimetic (growth hormone secretagogue)
- Off-label GH stimulation
- No published VAT-specific trials
- 200–300mcg SQ 2–3x daily
- $180–$350
- Lower cost but requires multiple daily injections; no robust VAT evidence
- Sermorelin
- GHRH analogue (1-29 fragment)
- Minimal published VAT data
- 200–500mcg SQ daily
- $200–$400
- Shorter half-life than tesamorelin; less clinical evidence for fat reduction